In this PharmaTalk podcast, Benjamine Liu, DPhil, CEO of TrialSpark, discusses the impacts of COVID-19 on the future of clinical research and the innovation being created as a result. Ben recently spoke at DPHARM: Disruptive Innovations to Advance Clinical Trials, moderating an R&D leadership fireside chat with Drs Mark Fishman and Michel Mina.
In this podcast, he recently spoke with DPHARM writer Danny McCarthy about:
Ben will be demonstrating the value of OpenAI's GPT-3 natural language processing model and artificial intelligence at an upcoming webinar, October 22 at 1pm EST. For more information and to register to attend, go to theconferenceforum.org.
Benjamine Liu, DPhil, is the co-founder and CEO of TrialSpark, a technology company that is reimagining drug development. TrialSpark partners with doctors to create FDA compliant trial sites within their existing practices (like Airbnb), unlocking the 99% of patients and doctors not involved in trials today and democratizing access to research treatments. TrialSpark runs trials out of these sites using a roaming cohort of research coordinators (like Instacart), optimized by software, data, and machine-learning.